Shire PLC (LON:SHP)‘s stock had its “buy” rating reiterated by stock analysts at Berenberg Bank in a note issued to investors on Tuesday. They currently have a GBX 5,800 ($75.71) price target on the biopharmaceutical company’s stock. Berenberg Bank’s price objective would suggest a potential upside of 13.55% from the stock’s previous close.
A number of other analysts have also weighed in on SHP. Deutsche Bank AG reissued a “buy” rating and issued a GBX 5,600 ($73.10) price target on shares of Shire PLC in a report on Tuesday, May 31st. Credit Suisse Group AG reissued an “outperform” rating and issued a GBX 5,000 ($65.27) price target on shares of Shire PLC in a report on Wednesday, June 1st. JPMorgan Chase & Co. reissued an “overweight” rating and issued a GBX 5,600 ($73.10) price target on shares of Shire PLC in a report on Wednesday, June 1st. Morgan Stanley reissued an “overweight” rating and issued a GBX 5,600 ($73.10) price target on shares of Shire PLC in a report on Friday, June 3rd. Finally, Jefferies Group raised their price target on shares of Shire PLC from GBX 5,150 ($67.22) to GBX 6,050 ($78.97) and gave the company a “buy” rating in a report on Monday, June 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Shire PLC presently has an average rating of “Buy” and an average target price of GBX 5,828 ($76.07).
Shares of Shire PLC (LON:SHP) opened at 5108.00 on Tuesday. Shire PLC has a 12-month low of GBX 2,707.19 and a 12-month high of GBX 5,377.00. The stock has a 50 day moving average price of GBX 4,990.28 and a 200-day moving average price of GBX 4,501.92. The stock’s market cap is GBX 34.88 billion.
The business also recently disclosed a dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 8th will be given a GBX 3.51 ($0.05) dividend. The ex-dividend date is Thursday, September 8th. This represents a yield of 0.07%.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.